摘要
目的:研究甲磺酸伊马替尼治疗晚期胃肠道间质瘤近期疗效,及晚期胃肠道间质瘤临床病理特征与近期疗效的相关性。方法:对经甲磺酸伊马替尼,初始剂量为400mg/日,治疗的36例晚期乳腺癌患者进行回顾性分析,结合患者的临床病理学资料,将研究对象分为不同亚组,观察不同亚组间甲磺酸伊马替尼治疗晚期胃肠道间质瘤的近期有效率(RR)差异及治疗的不良反应。结果:该组GIST患者甲磺酸伊马替尼治疗的近期有效率为19例(52.8%),不同的转移病灶部位(P=0.048)的RR率有显著差异。该方案的毒副反应主要为水肿20例(55.6%),恶心17例(47.2%),呕吐8例(22.2%),且均可防控。结论:甲磺酸伊马替尼对晚期胃肠道间质瘤有较好的疗效,其近期有效率与转移灶部位密切相关。
Objective： This study is to investigate the effect of imatinib mesylate on advanced the gastrointestinal stromal tumors （GISTs） and the relationship of curative effect and clinic pathological features. Methods： After treated by imatinib mesylate with starting doses of 400mg/day, the clinic pathological data of 36 advanced gastrointestinal stromal tumors patients were analyzed retrospectively. The patients were divided into different subgroups .Then the short-term effect ofImatinib mesylate among different subgroups and treatment adverse were detected. Results The recent response rate of patients with Imatinib mesylate was 19 cases （52.8%）, and the RR with different metastatic sites （P = 0.048） were significantly different. The treatment adverse： edema 20 cases （55.6%）, nausea 17 cases （47.2%）, and vomit 8 cases （22.2%）. And all adverse reactions can be controlled well. Conclusions： Imatinib mesylate has good effect on advanced gastrointestinal stromal tumor. The efficacy is closely related with the metastatic sites.
出处
《现代生物医学进展》
CAS
2010年第22期4258-4260,共3页
Progress in Modern Biomedicine
关键词
甲磺酸伊马替尼
胃肠道间质瘤
转移
复发
Imatinib mesylate
Gastrointestinal Stromal Tumors
Metastasis
Recur
